CA2300165A1 - Therapie hypocholesterolemiante - Google Patents

Therapie hypocholesterolemiante Download PDF

Info

Publication number
CA2300165A1
CA2300165A1 CA002300165A CA2300165A CA2300165A1 CA 2300165 A1 CA2300165 A1 CA 2300165A1 CA 002300165 A CA002300165 A CA 002300165A CA 2300165 A CA2300165 A CA 2300165A CA 2300165 A1 CA2300165 A1 CA 2300165A1
Authority
CA
Canada
Prior art keywords
subject
hmg
coa reductase
reductase inhibitor
fatal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002300165A
Other languages
English (en)
Inventor
Edwin J. Whitney
Geraldine Mantell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814415.7A external-priority patent/GB9814415D0/en
Priority claimed from GBGB9815851.2A external-priority patent/GB9815851D0/en
Application filed by Individual filed Critical Individual
Publication of CA2300165A1 publication Critical patent/CA2300165A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes de prévention ou de réduction du risque d'un premier accident cardio-vasculaire, à l'aide d'un inhibiteur de HMG-CoA-réductase seul ou en combinaison avec un autre agent modifiant les lipides. Les sujets à traiter sont ceux qui présentent un taux de cholestérol total sérique moyen, un taux sérique de cholestérol dans les lipoprotéines de basse densité moyen à légèrement élevé et un taux sérique de cholestérol dans les lipoprotéines de haute densité en dessous de la moyenne, sans antécédents de maladies coronariennes cliniquement déclarées.
CA002300165A 1997-08-26 1998-08-21 Therapie hypocholesterolemiante Abandoned CA2300165A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US5696697P 1997-08-26 1997-08-26
US60/056,966 1997-08-26
US7685998P 1998-03-05 1998-03-05
US60/076,859 1998-03-05
US8536098P 1998-05-13 1998-05-13
US60/085,360 1998-05-13
GBGB9814415.7A GB9814415D0 (en) 1998-07-03 1998-07-03 Cholesterol-lowering therapy
GB9814415.7 1998-07-03
GBGB9815851.2A GB9815851D0 (en) 1998-07-21 1998-07-21 Cholesterol-lowering therapy
GB9815851.2 1998-07-21
PCT/US1998/017459 WO1999009967A2 (fr) 1997-08-26 1998-08-21 Therapie hypocholesterolemiante

Publications (1)

Publication Number Publication Date
CA2300165A1 true CA2300165A1 (fr) 1999-03-04

Family

ID=27517467

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002300165A Abandoned CA2300165A1 (fr) 1997-08-26 1998-08-21 Therapie hypocholesterolemiante

Country Status (4)

Country Link
EP (1) EP1007019A2 (fr)
AU (1) AU9115398A (fr)
CA (1) CA2300165A1 (fr)
WO (1) WO1999009967A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2042526A1 (fr) * 1990-06-11 1991-12-12 Adeoye Y. Olukotun Methode permettant de prevenir une deuxieme crise cardiaque a l'aide d'un inhibiteur de la hmg coa-reductase
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
CA2070149A1 (fr) * 1991-06-04 1992-12-05 Stephen J. Boccuzzi Inhibiteurs de la reductase hmg-coa utilises pour la prevention de la restenose suivant une angioplastie coronarienne
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor

Also Published As

Publication number Publication date
WO1999009967A3 (fr) 1999-05-20
EP1007019A2 (fr) 2000-06-14
WO1999009967B1 (fr) 1999-07-08
WO1999009967A2 (fr) 1999-03-04
AU9115398A (en) 1999-03-16

Similar Documents

Publication Publication Date Title
US6180660B1 (en) Cholesterol-lowering therapy
EP1009400B1 (fr) Therapie combinee utilisant de l'atorvastatine et un antihypertenseur
EP1491193B1 (fr) Combinaisons thérapeutiques contenant de l'amlodipine et de l'atorvastatine
Andrus Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature
US6673831B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
EP0671171A1 (fr) Utilisation d'inhibiteurs de la HMG CoA, réductase dans la fabrication d'un médicament pour réduire ou prevenir les risques d'attaques cardiaques
AP1207A (en) Combination therapy.
CA2251972A1 (fr) Therapie combinatoire pour reduire les risques associes a une maladie cardiovasculaire
CN1373753A (zh) 氨氮地平和阿托伐他汀的公共盐
JPH04225916A (ja) 脂血障害の治療用組成物
JP2002508320A (ja) スタチン−カルボキシアルキルエーテル配合物
EP0475148A1 (fr) Pravastatine seule ou en combinaison avec un dérivé de l'acide fibrique pour prévenir l'apparition ou traiter l'hyperlipoprotéinémie de type III
Marangos et al. Absorption of ciprofloxacin in patients with diabetic gastroparesis
JP4880685B2 (ja) 薬物による不整脈の発生を低減するための組成物
US20020103251A1 (en) Cholesterol-lowering therapy
CA2300165A1 (fr) Therapie hypocholesterolemiante
Morgan et al. Simvastatin in the treatment of hypercholesterolaemia in patients with essential hypertension
US20060252814A1 (en) Formulation comprising a betablocker and optionally a cholestrol-lowering agent
JP2003524582A (ja) 抗高脂血症性スタチン−Ｌｐ（ａ）阻害剤配合物
JP2003531170A (ja) 抗高血圧剤および使用
US20040092574A1 (en) Statin-Lp(a) inhibitor combinations
Smith New Trends in Lipid Management: Eight Cases to Consider.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued